SG10202010814RA - Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof - Google Patents
Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereofInfo
- Publication number
- SG10202010814RA SG10202010814RA SG10202010814RA SG10202010814RA SG10202010814RA SG 10202010814R A SG10202010814R A SG 10202010814RA SG 10202010814R A SG10202010814R A SG 10202010814RA SG 10202010814R A SG10202010814R A SG 10202010814RA SG 10202010814R A SG10202010814R A SG 10202010814RA
- Authority
- SG
- Singapore
- Prior art keywords
- improved methods
- vaccine compositions
- compositions obtained
- dose reduced
- reduced vaccine
- Prior art date
Links
- 241000709661 Enterovirus Species 0.000 title 1
- 239000002671 adjuvant Substances 0.000 title 1
- 230000002779 inactivation Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000001179 sorption measurement Methods 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/06—Inactivation or attenuation by chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32661—Methods of inactivation or attenuation
- C12N2770/32663—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32671—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3180MU2014 | 2014-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202010814RA true SG10202010814RA (en) | 2020-12-30 |
Family
ID=55300742
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201702838SA SG11201702838SA (en) | 2014-10-07 | 2015-10-06 | Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof |
| SG10202010814RA SG10202010814RA (en) | 2014-10-07 | 2015-10-06 | Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201702838SA SG11201702838SA (en) | 2014-10-07 | 2015-10-06 | Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US10485862B2 (enExample) |
| EP (2) | EP3204494B1 (enExample) |
| JP (2) | JP6755243B2 (enExample) |
| KR (2) | KR102219638B1 (enExample) |
| CN (2) | CN113368227A (enExample) |
| AU (2) | AU2015334495B2 (enExample) |
| CA (1) | CA2963897C (enExample) |
| CU (1) | CU24510B1 (enExample) |
| CY (1) | CY1123078T1 (enExample) |
| DK (1) | DK3204494T3 (enExample) |
| EA (1) | EA201700187A1 (enExample) |
| ES (1) | ES2803578T3 (enExample) |
| HU (1) | HUE049104T2 (enExample) |
| LT (1) | LT3204494T (enExample) |
| MX (1) | MX388525B (enExample) |
| MY (1) | MY204389A (enExample) |
| PE (1) | PE20171132A1 (enExample) |
| PH (1) | PH12017500627A1 (enExample) |
| PL (1) | PL3204494T3 (enExample) |
| PT (1) | PT3204494T (enExample) |
| SG (2) | SG11201702838SA (enExample) |
| SI (1) | SI3204494T1 (enExample) |
| UA (1) | UA125788C2 (enExample) |
| WO (1) | WO2016063291A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2963897C (en) * | 2014-10-07 | 2023-08-22 | Serum Institute Of India Private Limited | Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof |
| WO2017197034A1 (en) | 2016-05-10 | 2017-11-16 | Najit Technologies, Inc. | Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production |
| EA201900117A1 (ru) * | 2016-08-26 | 2019-09-30 | Серум Инститьют Оф Индиа Прайвит Лимитид | Комбинированная вакцина и способ её производства (варианты) |
| TWI711700B (zh) * | 2017-07-10 | 2020-12-01 | 印度商印度血清研究公司 | 使腸病毒去活化之改良方法、佐劑吸附及所獲得之劑量減少的疫苗組成物 |
| WO2019090233A2 (en) | 2017-11-03 | 2019-05-09 | Takeda Vaccines, Inc. | Method for inactivating zika virus and for determining the completeness of inactivation |
| JP7443233B2 (ja) | 2017-11-30 | 2024-03-05 | タケダ ワクチン，インコーポレイテッド | ジカウイルスを不活性化する方法及び関連する方法 |
| EP3749757A4 (en) | 2018-02-07 | 2021-11-24 | Bharat Biotech International Limited | PROCESS FOR PURIFICATION AND INACTIVATION OF ENTERVIRUSES AND VACCINE COMPOSITIONS OBTAINED THEREOF |
| CN109550046B (zh) * | 2018-12-21 | 2020-08-25 | 北京民海生物科技有限公司 | 一种吸附无细胞百白破-脊髓灰质炎-b型流感嗜血杆菌联合疫苗及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0914153T3 (da) * | 1996-07-02 | 2007-01-29 | Sanofi Pasteur Ltd | Multivalente DTP-poliovacciner |
| EA010057B1 (ru) * | 2004-08-27 | 2008-06-30 | Панацея Биотек Лтд. | Инактивированная полиомиелитная вакцина, полученная из штамма сейбина вируса полиомиелита |
| CN1647822A (zh) * | 2005-02-06 | 2005-08-03 | 北京生物制品研究所 | 脊髓灰质炎灭活疫苗及其制备方法 |
| SI2097102T1 (sl) * | 2006-09-07 | 2012-09-28 | Glaxosmithkline Biolog Sa | Kombinirano cepivo, ki ima zmanjšane količine antigena za poliovirus |
| CN100540662C (zh) * | 2006-12-06 | 2009-09-16 | 云南沃森生物技术有限公司 | 一种混合床凝胶过滤层析技术用于病毒性疫苗纯化的方法 |
| WO2010036226A1 (en) * | 2008-09-26 | 2010-04-01 | George Nelson | Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis |
| CN102655879B (zh) | 2009-12-16 | 2016-03-09 | 印度血清研究所 | 疫苗组合物 |
| TR201811280T4 (tr) * | 2011-03-02 | 2018-08-27 | Glaxosmithkline Biologicals Sa | Düşük antijen ve/ veya adjuvan dozları olan karma aşılar. |
| GB201105981D0 (en) * | 2011-04-08 | 2011-05-18 | Glaxosmithkline Biolog Sa | Novel process |
| CA2963897C (en) | 2014-10-07 | 2023-08-22 | Serum Institute Of India Private Limited | Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof |
-
2015
- 2015-10-06 CA CA2963897A patent/CA2963897C/en active Active
- 2015-10-06 EA EA201700187A patent/EA201700187A1/ru unknown
- 2015-10-06 HU HUE15831237A patent/HUE049104T2/hu unknown
- 2015-10-06 DK DK15831237.1T patent/DK3204494T3/da active
- 2015-10-06 WO PCT/IN2015/000376 patent/WO2016063291A1/en not_active Ceased
- 2015-10-06 PE PE2017000562A patent/PE20171132A1/es unknown
- 2015-10-06 KR KR1020177012227A patent/KR102219638B1/ko active Active
- 2015-10-06 SG SG11201702838SA patent/SG11201702838SA/en unknown
- 2015-10-06 PL PL15831237T patent/PL3204494T3/pl unknown
- 2015-10-06 SG SG10202010814RA patent/SG10202010814RA/en unknown
- 2015-10-06 ES ES15831237T patent/ES2803578T3/es active Active
- 2015-10-06 SI SI201531223T patent/SI3204494T1/sl unknown
- 2015-10-06 CN CN202110677385.5A patent/CN113368227A/zh active Pending
- 2015-10-06 MX MX2017004534A patent/MX388525B/es unknown
- 2015-10-06 AU AU2015334495A patent/AU2015334495B2/en active Active
- 2015-10-06 MY MYPI2017703783A patent/MY204389A/en unknown
- 2015-10-06 CN CN201580066368.0A patent/CN106999569B/zh active Active
- 2015-10-06 EP EP15831237.1A patent/EP3204494B1/en active Active
- 2015-10-06 CU CU2017000044A patent/CU24510B1/es unknown
- 2015-10-06 PT PT158312371T patent/PT3204494T/pt unknown
- 2015-10-06 EP EP20154738.7A patent/EP3663396A1/en active Pending
- 2015-10-06 US US15/517,225 patent/US10485862B2/en active Active
- 2015-10-06 JP JP2017518817A patent/JP6755243B2/ja active Active
- 2015-10-06 UA UAA201704367A patent/UA125788C2/uk unknown
- 2015-10-06 KR KR1020217004836A patent/KR102510744B1/ko active Active
- 2015-10-06 LT LTEP15831237.1T patent/LT3204494T/lt unknown
-
2017
- 2017-04-05 PH PH12017500627A patent/PH12017500627A1/en unknown
-
2020
- 2020-06-25 CY CY20201100591T patent/CY1123078T1/el unknown
- 2020-08-25 JP JP2020142117A patent/JP7063957B2/ja active Active
-
2021
- 2021-11-18 AU AU2021269395A patent/AU2021269395B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201904717B (en) | Therapeutic hpv18 vaccines | |
| IL247309A0 (en) | Preparations for inhibiting virus replication and methods for their preparation and use | |
| LT3206497T (lt) | Kompozicijos ir būdai, skirti meibomo liaukos disfunkcijos gydymui | |
| ZA201700952B (en) | Indoles for use in influenza virus infection | |
| SG10202010814RA (en) | Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof | |
| IL273932A (en) | Methods of treatment and prevention of viral infection | |
| DK3204386T3 (da) | Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed | |
| LT3200815T (lt) | Būdai ir kompozicijos, skirti vėžio gydymui | |
| PT3020430T (pt) | Cânula para terapia de implantação de sutura catgut | |
| ZA201608487B (en) | Dual adjuvant vaccine compositions, preparation and uses | |
| IL251108A0 (en) | Preparations and methods for the treatment of acute radiation syndrome | |
| EP3166637A4 (en) | Compositions and methods for treating dengue virus infection | |
| PL3106459T3 (pl) | Podstawiona pirolem pochodna indolonu, sposób jej wytwarzania, zawierająca ją kompozycja i jej zastosowanie | |
| PL3331359T3 (pl) | Rolnicze kompozycje adiuwantowe i sposoby zastosowania takich kompozycji | |
| IL251101B (en) | Vaccine compounds comprising tryptophan 3,2-dioxygenase or fragments thereof | |
| PT3142641T (pt) | Formulações para o tratamento de hipertiroidismo | |
| PL3223846T3 (pl) | Kompozycje adiuwantowe i powiązane sposoby | |
| IL250553A0 (en) | Means and method for targeted medical treatment using x-rays | |
| EP3166957A4 (en) | Sulfated-glycolipids as adjuvants for vaccines | |
| PT3297666T (pt) | Adjuvante e vacina molecular | |
| GB201406755D0 (en) | Indigestion, angled adjustable bed | |
| GB201521083D0 (en) | Compositions for treatment and methods thereof | |
| SG10201400823PA (en) | Therapeutic methods and compositions for treating diabetes | |
| GB201419559D0 (en) | Therapeutic compositions and methods | |
| GB201405857D0 (en) | Immunogenic formulations |